Dampening Logistics Creating Inequitable Access: A Major Threat Despite Advancements

We read with great interest the recent publication by Shahzad et al. titled “Geographic and Racial Disparities in Chimeric Antigen Receptor–T Cells and Bi-specific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma” which is a report on the distribution across the US of chimeric antigen receptor T cell (CART) and bispecific therapies.1 Shahzad et al. demonstra ted that the 126 studies were distributed over 31 states, however, there is considerable variation by region in the availability of the trial.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Commentary Source Type: research